BioTuesdays

Tag - CBAY

CymaBay

HCW ups CymaBay Therapeutics to buy; PT $9

H.C. Wainwright upgraded CymaBay Therapeutics (NASDAQ:CBAY) to “buy” from “neutral,” with a price target of $9, citing a possible lifting of the clinical hold on seladelpar development in liver disease. The stock closed...

CymaBay

Analysts upgrade CymaBay Therapeutics and raise PTs

Analysts for Stifel, SVB Leerink and Roth Capital Partners upgraded CymaBay Therapeutics (NASDAQ:CBAY) and raised their price targets, citing a unanimous vote by an independent review that recommend further development...

CymaBay

Stifel cuts CymaBay to hold; PT to $4 from $14

Stifel downgraded CymaBay Therapeutics (NASDAQ:CBAY) to “hold” from “buy” and slashed its price target to $4 from $14 after the company halted development of its sole value driver, seladelpar. The stock closed at $5.55...

CymaBay

Roth ups CymaBay price target to $6

Roth Capital Partners raised its price target for CymaBay Therapeutics (NASDAQ:CBAY) to $6 from $4, citing a potential partnership for the company’s gout product. The stock closed at $1.79 on Thursday. “Following...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.